SCHEMBL1374209

SCHEMBL1374209

O=c1ccc(-c2ccc(OCCCN3CCOCC3)cc2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 15/20 1.00
HTR3A P46098 4/20 0.61
CHRM2 P08172 2/20 0.61
KCNH2 Q12809 2/20 0.61
SLC6A2 P23975 1/20 0.61
ADRA1A P35348 1/20 0.61
SLC6A3 Q01959 1/20 0.61
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CHRM1 P11229 1/20 0.55
HTR2A P28223 1/20 0.55
SCN1A P35498 1/20 0.55
HTR2B P41595 1/20 0.55
SCN2A Q99250 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
SCN3A Q9NY46 1/20 0.55
HRH2 P25021 1/20 0.55
HRH1 P35367 1/20 0.55
USP2 O75604 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1373074 0.89 HRH3 (1.00) HRH3HTR3ACHRM2KCNH2SLC6A2
SCHEMBL1373297 0.88 HRH3 (1.00) HRH3HTR3ACHRM2KCNH2SLC6A2
SCHEMBL10197826 0.80 HRH3 (0.66) HRH3CHRM2KCNH2MAPK1ALDH1A1
SCHEMBL12595948 0.77 HRH3 (0.62) HRH3
SCHEMBL10196775 0.77 HRH3 (0.66) HRH3HTR3ACHRM2KCNH2SLC6A2
SCHEMBL3604079 0.77 HRH3 (0.66) HRH3HTR3ACHRM2KCNH2SLC6A2
Irdabisant SCHEMBL117723 0.76 HRH3 (1.00) HRH3HTR3ACHRM2KCNH2SLC6A2
Irdabisant SCHEMBL118744 0.76 HRH3 (1.00) HRH3HTR3ACHRM2KCNH2SLC6A2
Irdabisant SCHEMBL1376185 0.76 HRH3 (1.00) HRH3HTR3ACHRM2KCNH2SLC6A2
Irdabisant SCHEMBL16040431 0.75 HRH3 (0.98) HRH3HTR3ACHRM2KCNH2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2492263-A1 Pyridizinone Derivatives Cephalon, Inc. (US) 2012-08-29 EP claimed
EP-2069312-A2 PYRIDIZINONE DERIVATIVES Cephalon, Inc. (US) 2009-06-17 EP claimed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO claimed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US claimed
EP-2502918-B1 Pyridazinone Derivatives CEPHALON INC (US) 2015-03-25 EP disclosed
EP-2502918-B1 Pyridazinone Derivatives CEPHALON INC (US) 2015-03-25 EP disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
EP-2069312-A2 PYRIDIZINONE DERIVATIVES Cephalon, Inc. (US) 2009-06-17 EP disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027041-A1 Pyridizinone derivatives H1-5, H1-3, H1-4 HRH3 4/4885HTR3A 347/4885CHRM2 357/4885
US-20140142088-A1 PYRIDAZINONE DERIVATIVES HRH3, HNMT, HRH4 HRH3 1/4885HTR3A 17/4885CHRM2 84/4885
US-20100273779-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 HRH3 1/4885HTR3A 15/4885CHRM2 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.